C2N at CTAD 2024 in Madrid
C2N Diagnostics, LLC, a leader in advanced brain health diagnostics, is adding to its evidence-based legacy at the Clinical Trials for Alzheimer’s Disease (CTAD) 2024 conference in Madrid October 29 – November 1.
C2N continues to set a standard in innovation in Alzheimer’s disease diagnostics through numerous presentations by esteemed researchers and clinicians at CTAD. Join us in Madrid and be among the first to learn about exciting new data for the Precivity™ line of blood tests.
We encourage you to click this link to schedule a meeting with our team.
All sessions and posters will be held at the Madrid Marriott Auditorium Hotel & Convention Center.
8 sessions and 5 posters will offer novel insights relating to the Precivity™ blood tests. These presentations/posters include:
Presentations by C2N Executives
Be the first to hear:
Monday, October 28 (Invite Only)
ADDF Summit: Advances in Novel Therapeutics and Combination Therapy
Dr. Braunstein featured on panel discussing: "Future of Alzheimer’s Biomarkers in Clinical Care and Research"
Friday, November 1 Sessions
10:00 a.m. CEST
Dr. Joel Braunstein, CEO, presents a session on: An evaluation of the impact of a multi-analyte blood biomarker test for evaluating cognitive impairment: Results of the QUIP II clinical utility study.
12:15 p.m. CEST
Dr. Sheena Aurora, Vice President of Neurology, on a Late Breaking Panel to discuss: Plasma P-tau217 assays in clinical practice: Current uses and future considerations for diagnosing Alzheimer’s disease.
Sessions on C2N's Test Data
Tuesday, October 29
5:40 p.m. – 5:55 p.m. CEST
0C4 - Anti-tau therapeutic antibody, E2814, reduces early and late tau pathology biomarkers in patients with DIAD
6:10 p.m. – 6:50 p.m. CEST
Late breaking Symposium 1 - The AHEAD 3-45 Study: Design and Results of a Novel Screening Process for a Preclinical AD Trial
Wednesday, October 30
5:25 p.m. – 5:40 p.m. CEST
0C18 – Blood biomarkers to detect Alzheimer’s disease in clinical practice— a cross-sectional study in primary and secondary care
Thursday, October 31
8:30 a.m. – 8:45 a.m. CEST
LB7: Plasma p-tau217 and related CSF proteomic markers of pathological progression are slowed by p75NTR modulation: A Phase 2a trial of LM11A31 in Alzheimer’s disease
1:55 p.m. – 2:20 p.m. CEST
Keynote 4: Fluid biomarkers in research, clinical trials, and clinical practice
Friday, November 1
9:00 a.m. – 9:15 a.m. CEST
LB22: Timing of changes in Alzheimer’s disease plasma biomarkers using amyloid and tau PET clocks
10:00 a.m. – 10:15 a.m. CEST
0C32 – An evaluation of the impact of a multi-analyte blood biomarker test for evaluating cognitive impairment: Results of the QUIP II clinical utility study
12:15 p.m. – 12:45 p.m. CEST
LATE BREAKING ROUNDTABLE: Plasma P-tau217 assays in clinical practice: Current uses and future considerations for diagnosing Alzheimer’s disease
Poster Sessions
Poster Session 1
Tuesday, October 29 – 3:00 p.m. to Wednesday, October 30 – 5:00 p.m. CEST
P007 Using plasma pTau217 ratio to forecast longitudinal progression substantially increases the efficiency of AD clinical trials
Poster Session 2
Thursday October 31 – 7:15 a.m. to Friday, November 1 – 5:00 p.m CEST
LP054 Biomarker Evaluation in Young Onset Dementia from Diverse Populations (BEYONDD)
P072 Diagnostic Performance of Plasma Alzheimer’s Disease Biomarkers for Predicting Amyloid/Tau/Neurodegeneration
Poster Session 3
Friday, November 1 – 7:15 a.m. – 5:00 p.m. CEST
P199 Sequential Administration of Digital Testing to Screen For Cognitive Impairment Followed By Blood Based Biomarkers To Assist With Timely Detection And Accurate Diagnosis of Alzheimer’s Disease in AdventHealth
P200 Clinical Management during the Davos Alzheimer’s Collaborative Early Detection of Cognitive Impairment Program in Six Countries
We encourage you to click this link to schedule a meeting with our team. We look forward to seeing you in Madrid!
About C2N Diagnostics, LLC
C2N Diagnostics is a specialty diagnostics company with a vision to bring Clarity Through Innovation™. C2N strives to provide exceptional laboratory services and products in the field of brain health. C2N’s biomarker services and products are used for: clinical decision making to improve patient care, including diagnosis and treatment monitoring; maximizing the quality and efficiency of clinical trials that test novel treatments for neurodegeneration; and providing innovative tools to help healthcare researchers better understand novel mechanisms of disease, identify new treatment targets, and conduct important epidemiologic studies to improve global public health. For more information visit www.C2N.com.